novartis vas narasimhan news - Search News

Novartis not joining 'frenzy' of weight loss drugs, CEO says

CNBC on MSN · 2d

Novartis not joining the 'frenzy' of weight loss drugs, CEO says

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Benzinga on MSN · 1d

Novartis Skips Weight Loss Drug 'Frenzy,' Focuses on 'Unique Position' for Cancer, Alzheimers, and Parkinsons Treatments

Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated by Novo Nordisk and Eli Lilly. Novartis will instead focus on areas where it can build a “unique position,

invezz on MSN · 1d

How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market

As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different path. While competitors like Eli Lilly and Novo Nordisk race to capture the booming weight-loss drug market,

BayStreet · 1d

Novartis Steers Clear of Weight Loss Drug “Frenzy”

The CEO of Novartis (NYSE:NVS) said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.

1don MSN

Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

14don MSN

Jim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’

We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

Lilly on alert as new Kisqali approval threatens Verzenio

Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...

ENDPOINTS NEWS2d

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...

15d

Top 10 Stocks on Jim Cramer’s Radar

In this article, we’ll explore the Top 10 Stocks on Jim Cramer’s Radar. Jim Cramer often reflects on how he would reform the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results